# Anti-Malarial Drug Resistance in Cameroon

> **NCT00146718** · PHASE2,PHASE3 · COMPLETED · sponsor: **London School of Hygiene and Tropical Medicine** · enrollment: 755 (—)

## Conditions studied

- Malaria

## Interventions

- **DRUG:** Amodiaquine and Sulphadoxine/Pyrimethamine

## Key facts

- **NCT ID:** NCT00146718
- **Lead sponsor:** London School of Hygiene and Tropical Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-08
- **Primary completion:** —
- **Final completion:** 2005-05
- **Target enrollment:** 755 (—)
- **Last updated:** 2017-01-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00146718

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00146718, "Anti-Malarial Drug Resistance in Cameroon". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT00146718. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*